- Home
- LYEL vs JSPRW Comparison
LYEL vs JSPRW Comparison
Compare LYEL & JSPRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- JSPRW
- Stock Information
- Founded
- LYEL 2018
- JSPRW N/A
- Country
- LYEL United States
- JSPRW United States
- Employees
- LYEL N/A
- JSPRW 45
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- JSPRW Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- JSPRW Health Care
- Exchange
- LYEL Nasdaq
- JSPRW Nasdaq
- Market Cap
- LYEL 263.9M
- JSPRW N/A
- IPO Year
- LYEL 2021
- JSPRW 2020
- Fundamental
- Price
- LYEL $0.65
- JSPRW $0.22
- Analyst Decision
- LYEL Sell
- JSPRW
- Analyst Count
- LYEL 2
- JSPRW 0
- Target Price
- LYEL $1.00
- JSPRW N/A
- AVG Volume (30 Days)
- LYEL 1.3M
- JSPRW N/A
- Earning Date
- LYEL 02-26-2025
- JSPRW N/A
- Dividend Yield
- LYEL N/A
- JSPRW N/A
- EPS Growth
- LYEL N/A
- JSPRW N/A
- EPS
- LYEL N/A
- JSPRW N/A
- Revenue
- LYEL $63,000.00
- JSPRW N/A
- Revenue This Year
- LYEL N/A
- JSPRW N/A
- Revenue Next Year
- LYEL N/A
- JSPRW N/A
- P/E Ratio
- LYEL N/A
- JSPRW N/A
- Revenue Growth
- LYEL N/A
- JSPRW N/A
- 52 Week Low
- LYEL $0.58
- JSPRW N/A
- 52 Week High
- LYEL $3.26
- JSPRW N/A
- Technical
- Relative Strength Index (RSI)
- LYEL 34.74
- JSPRW N/A
- Support Level
- LYEL $0.60
- JSPRW N/A
- Resistance Level
- LYEL $0.71
- JSPRW N/A
- Average True Range (ATR)
- LYEL 0.06
- JSPRW 0.00
- MACD
- LYEL 0.01
- JSPRW 0.00
- Stochastic Oscillator
- LYEL 23.51
- JSPRW 0.00
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About JSPRW Japer Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.